30
Jun
2010
BIND Biosciences, Inc.: Series C $12.4M
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Inflammation, X - Oncology, X - Therapeutic Platform, XX - MA
Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.
OnBioVC PARTNERS
-
